• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

CXCR4 has a dual role in improving the efficacy of BCMA-redirected CAR-NK cells in multiple myeloma

by | Jul 9, 2024 | Publications

Front Immunol. 2024 Jun 24;15:1383136. doi: 10.3389/fimmu.2024.1383136. eCollection 2024. ABSTRACT Multiple myeloma (MM) is a plasma cell disease with a preferential bone marrow (BM) tropism. Enforced expression of tissue-specific chemokine receptors has been shown to...

A Rare Cause of Dyspnea in a Patient with Multiple Myeloma: Tracheobronchial Amyloidosis

by | Jul 9, 2024 | Publications

Turk J Haematol. 2024 Jul 9. doi: 10.4274/tjh.galenos.2024.2024.0188. Online ahead of print. NO ABSTRACT PMID:38979562 | DOI:10.4274/tjh.galenos.2024.2024.0188

Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN

by | Jul 9, 2024 | Publications

Blood Cancer J. 2024 Jul 8;14(1):107. doi: 10.1038/s41408-024-01088-6. ABSTRACT The randomized, phase 2 GRIFFIN study (NCT02874742) evaluated daratumumab plus lenalidomide/bortezomib/dexamethasone (D-RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM)....

Synergistic effect of FOXM1 and BCL-2 inhibition in a preclinical treatment study on multiple myeloma

by | Jul 9, 2024 | Publications

J Transl Med. 2024 Jul 8;22(1):638. doi: 10.1186/s12967-024-05452-9. NO ABSTRACT PMID:38977990 | DOI:10.1186/s12967-024-05452-9

Albumin-to-Globulin Ratio Combined with Neutrophil-to-Lymphocyte Ratio as a Prognostic Predictor in Multiple Myeloma with Renal Impairment

by | Jul 8, 2024 | Publications

Blood Lymphat Cancer. 2024 Jul 2;14:49-62. doi: 10.2147/BLCTT.S468836. eCollection 2024. ABSTRACT BACKGROUND: The albumin-to-globulin ratio (AGR) and neutrophil-to-lymphocyte ratio (NLR) have been recently regarded as promising prognostic factors in various...

Biological relapse in multiple myeloma: Outcome and treatment strategies in a Spanish real-world setting

by | Jul 8, 2024 | Publications

Hemasphere. 2024 Jul 4;8(7):e81. doi: 10.1002/hem3.81. eCollection 2024 Jul. ABSTRACT Recommendations regarding the best time to start treatment in patients with relapsed/refractory multiple myeloma (RRMM) after biological relapse/progression (BR) are unclear. This...
« Older Entries
Next Entries »

Recent Content

  • FDA Update: Darzalex Faspro Not Approved for Multiple Myeloma
  • Temporal genomic dynamics shape clinical trajectory in multiple myeloma
  • Bone Marrow Microenvironments Vary Widely in Multiple Myeloma, Study Finds
  • Safety and efficacy of BCMA CAR-T vs. bispecific antibodies in patients with relapsed multiple myeloma: a systematic review and meta-analysis
  • Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma
  • Why New Patients With Multiple Myeloma ‘Can Expect Long, Healthy Lives’
  • Future Perspectives in Multiple Myeloma
  • Patients and Caregivers Aim to Raise Funds for Myeloma Research
  • GPRC5D Bispecific antibody talquetamab-induced dizziness-ataxia syndrome, clinical presentation and management- a case series
  • Symptomatic progression-free survival as an emerging patient-centered endpoint in multiple myeloma: a secondary analysis of MagnetsiMM-3 trial data
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT